



**Universiteit  
Leiden**  
The Netherlands

**Correction to: Neoadjuvant Systemic Therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC)**

Akkooi, A.C.J. van; Hieken, T.J.; Burton, E.M.; Ariyan, C.; Ascierto, P.A.; Asero, S.V.M.A.; ...  
; Int Neoadjuvant Melanoma Consortiu

**Citation**

Akkooi, A. C. J. van, Hieken, T. J., Burton, E. M., Ariyan, C., Ascierto, P. A., Asero, S. V. M. A., ... Ross, M. I. (2022). Correction to: Neoadjuvant Systemic Therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). *Annals Of Surgical Oncology*, 29(8), 5241-5242.  
doi:10.1245/s10434-022-11622-0

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3589657>

**Note:** To cite this publication please use the final published version (if applicable).



CORRECTION

## Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Alexander C. J. van Akkooi, MD, PhD<sup>1</sup>, Tina J. Hieken, MD<sup>2</sup>, Elizabeth M. Burton, MBA<sup>3</sup>, Charlotte Ariyan, MD, PhD<sup>4</sup>, Paolo A. Ascierto, MD, BC<sup>5</sup>, Salvatore V. M. A. Asero, MD, PhD<sup>6</sup>, Christian U. Blank, MD, PhD<sup>1</sup>, Matthew S. Block, MD, PhD<sup>2</sup>, Genevieve M. Boland, MD, PhD<sup>7</sup> , Corrado Caraco, MD, PhD<sup>5</sup>, Sydney Chng, MBBS, PhD, FRACS<sup>8,9,10</sup>, B. Scott Davidson, MD<sup>11</sup>, Joao Pedreira Duprat Neto, MD, PhD<sup>12</sup>, Mark B. Faries, MD<sup>13</sup>, Jeffrey E. Gershenwald, MD, FACS, FAAAS<sup>3</sup>, Dirk J. Grunhagen, MD, PhD<sup>14</sup>, David E. Gyorki, MBBS, MD, FRACS<sup>15</sup>, Dale Han, MD<sup>16</sup>, Andrew J. Hayes, MBBS, PhD<sup>17</sup>, Winan J. van Houdt, MD, PhD<sup>1</sup>, Giorgos C. Karakousis, MD, MS<sup>18</sup>, Willem M. C. Klop, MD, PhD<sup>1</sup>, Georgina V. Long, BSc, PhD, MBBS, FRACP, FAHMS<sup>8,10,19,20</sup>, Michael C. Lowe, MD, MA, FACS, FSSO<sup>21</sup>, Alexander M. Menzies, MBBS, PhD<sup>8,10,19,20</sup>, Roger Olofsson Bagge, MD, PhD<sup>22</sup>, Thomas E. Pennington, BSc, MBBS, MS, FRACS<sup>8,10</sup>, Piotr Rutkowski, MD, PhD<sup>23</sup>, Robyn P. M. Saw, MBBS, MS, FRACS<sup>8,9,10</sup>, Richard A. Scolyer, MBBS, MD, FRCPA, FRCPATH, FAHMS<sup>8,9,10</sup>, Kerwin F. Shannon, MBBS, FRACS<sup>8,10</sup>, Vernon K. Sondak, MD<sup>24</sup>, Hussein Tawbi, MD, PhD<sup>3</sup>, Alessandro A. E. Testori, MD<sup>25</sup>, Mike T. Tetzlaff, MD, PhD<sup>26</sup>, John F. Thompson, MD, FRACS, FACS<sup>8,9,10,20</sup>, Jonathan S. Zager, MD, FACS<sup>24</sup>, Charlotte L. Zuur, MD, PhD<sup>1,27</sup>, Jennifer A. Wargo, MD<sup>3</sup>, Andrew J. Spillane, MD<sup>8,10,19,20</sup>, Merrick I. Ross, MD<sup>3</sup> on behalf of International Neoadjuvant Melanoma Consortium (INMC)

<sup>1</sup>Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, TX; <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York City, NY; <sup>5</sup>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy; <sup>6</sup>Azienda di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania, Italy; <sup>7</sup>Massachusetts General Hospital, Boston, MA; <sup>8</sup>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; <sup>9</sup>Royal Prince Alfred Hospital, Sydney, NSW, Australia; <sup>10</sup>Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; <sup>11</sup>Northside Hospital Cancer Institute, Atlanta, GA; <sup>12</sup>AC Camargo Cancer Center, São Paulo, Brazil; <sup>13</sup>The Angeles Clinic, Cedars Sinai Medical Center, Los Angeles, CA; <sup>14</sup>Erasmus MC – Cancer Institute, Rotterdam, The Netherlands; <sup>15</sup>Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; <sup>16</sup>Oregon Health and Science University, Portland, Oregon; <sup>17</sup>Royal Marsden NHS Foundation Trust, London, UK; <sup>18</sup>Hospital of the University of Pennsylvania, Philadelphia, PA; <sup>19</sup>Royal North Shore Hospital, St. Leonards, NSW, Australia; <sup>20</sup>The Mater Hospital, North Sydney, NSW, Australia; <sup>21</sup>Winship Cancer Institute, Emory University, Atlanta, GA; <sup>22</sup>Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; <sup>23</sup>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; <sup>24</sup>Moffitt Cancer Center, Tampa, Florida; <sup>25</sup>Skin Oncology Division, Image Regenerative Clinic, Milan, Italy; <sup>26</sup>University of California San Francisco (UCSF), San Francisco, CA; <sup>27</sup>Department of Otorhinolaryngology, Leiden University Medical Center, Leiden, The Netherlands

The original article can be found online at <https://doi.org/10.1245/s10434-021-11236-y>.

© Society of Surgical Oncology 2022

Published Online: 15 April 2022

A. C. J. van Akkooi, MD, PhD  
e-mail: a.v.akkooi@nki.nl

**CORRECTION TO: ANN SURG ONCOL**[HTTPS://DOI.ORG/10.1245/S10434-021-11236-Y](https://doi.org/10.1245/S10434-021-11236-Y)

The authors' affiliations are correct as reflected here. Giorgos C. Karakousis's given name has also been corrected.

The original article was corrected.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.